Detection of the selective androgen receptor modulator andarine (S-4) in a routine equine blood doping control sample

2015 ◽  
Vol 8 (2) ◽  
pp. 257-261 ◽  
Author(s):  
Adam T. Cawley ◽  
Corrine Smart ◽  
Candace Greer ◽  
Marcus Liu Lau ◽  
John Keledjian
Keyword(s):  
Androgen Receptor ◽  
Control Sample ◽  
Doping Control ◽  
Blood Doping ◽  
Selective Androgen Receptor Modulator ◽  
Receptor Modulator

Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes

2017 ◽  
Vol 31 (14) ◽  
pp. 1175-1183 ◽  
Author(s):  
Mario Thevis ◽  
Thomas Piper ◽  
Josef Dib ◽  
Andreas Lagojda ◽  
Dirk Kühne ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Mass Spectrometric ◽  
Doping Control ◽  
Selective Androgen Receptor Modulator ◽  
Receptor Modulator

scholarly journals Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes

2021 ◽  
Author(s):  
Felicitas Wagener ◽  
Sven Guddat ◽  
Christian Görgens ◽  
Yiannis S. Angelis ◽  
Michael Petrou ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Limit Of Detection ◽  
Solid Phase ◽  
Doping Control ◽  
Urine Samples ◽  
Selective Androgen Receptor Modulator ◽  
Receptor Modulator ◽  
In Doping ◽  
Qualitative Detection ◽  
Result Management

AbstractLGD-4033 (ligandrol) is a selective androgen receptor modulator (SARM), which is prohibited in sports by the World Anti-Doping Agency (WADA) and led to 62 adverse analytical findings (AAFs) in 2019. But not only deliberate doping with LGD-4033 constitutes a problem. In the past years, some AAFs that concerned SARMs can be attributed to contaminated dietary supplements (DS). Thus, the urgency to develop methods to differentiate between inadvertent doping and abuse of SARMs to benefit from the performance-enhancing effect of the compound in sports is growing. To gain a better understanding of the metabolism and excretion patterns of LGD-4033, human micro-dose excretion studies at 1, 10, and 50 µg LGD-4033 were conducted. Collected urine samples were prepared for analysis using enzymatic hydrolysis followed by solid-phase extraction and analyzed via LC-HRMS/MS. Including isomers, a total of 15 phase I metabolites were detected in the urine samples. The LC-HRMS/MS method was validated for qualitative detection of LGD-4033, allowing for a limit of detection (LOD) of 8 pg/mL. The metabolite M1, representing the epimer of LGD-4033, was synthesized and the structure elucidated by NMR spectroscopy. As the M1/LGD-4033 ratio changes over time, the ratio and the approximate LGD-4033 concentration can contribute to estimating the time point of drug intake and dose of LGD-4033 in doping control urine samples, which is particularly relevant in anti-doping result management. Graphical abstract

Structural elucidation of major selective androgen receptor modulator (SARM) metabolites for doping control

2018 ◽  
Vol 16 (5) ◽  
pp. 698-702 ◽  
Author(s):  
Neeraj Garg ◽  
Annelie Hansson ◽  
Heather K. Knych ◽  
Scott D. Stanley ◽  
Mario Thevis ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Structural Elucidation ◽  
Doping Control ◽  
Selective Androgen Receptor Modulator ◽  
Drug Metabolites ◽  
Receptor Modulator

Elucidated and validated structure of the major SARM doping drug metabolites.

Safety and Tolerability of LGD-4033, a Novel Non-Steroidal Oral Selective Androgen Receptor Modulator (SARM), in Healthy Men

2011 ◽  
pp. P3-207-P3-207
Author(s):  
Shehzad Basaria ◽  
Lauren Collins ◽  
Melinda Sheffield-Moore ◽  
Edgar L Dillon ◽  
Katie Orwoll ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Selective Androgen Receptor Modulator ◽  
Healthy Men ◽  
Receptor Modulator
Sign in / Sign up

Export Citation Format

Share Document